Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
URTI, LRTI, skin and soft tissue and bone infections, joint infections, bactereamia. Clinical selection for Lincomycin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Adult oral dose: 500 mg 3 or 4 times daily, taken at least 1 or 2 hours before or after food. Given parenterally by I.M injection in a dose of 600mg once or twice daily, or by slow I.V infu- sion in a dose of 0.6 to 1g two or three times daily. Higher I.V doses have been given in very severe infections, up to a total daily dose of about 8g. For intravenous use, lincomycin 1g should be diluted in not less than 100mL of diluent and infused over at least 1 hour.
Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels.
Store as labelled. Keep out of reach of children.